16
2022-09
First patient dosed in CanWell’s CAN1012 Ph1 Trial in China
CanWell Biotech Ltd. , a company specializing in the development of innovative immune-oncology drugs, announced today that the 1st patient has been successfully dosed in its ongoing CAN1012 Ph1 clinical trial in China. The CAN1012 Phase I clinical trial is an open-label, multicenter, dose-escalation…
26
2022-07
CanWell’s TLR7 Agonist CAN1012 Received IND Approval by CDE in China
Canwell announced today that its TLR7 agonist CAN1012 had obtained clinical trial approval from China’s Center for Drug Evaluation (CDE). The approval allows CanWell to conduct Phase I clinical trials targeting advanced solid tumors in China. Prior to this, CAN1012 had obtained Phase I clinica…
18
2021-06
CanWell’s TLR7 Agonist CAN1012 IND Granted Approval by US FDA
CanWell Pharma announced that its innovative drug, TLR7 agonist CAN1012, has been granted clinical approval by the US Food and Drug Administration (FDA) and will soon conduct Phase I clinical trials for various solid tumors. CAN1012 is an innovative Toll-like receptor (TLR) 7 small mo…
05
2021-06
Professor Qiang Pan-Hammarström Named Member of Scientific Advisory Board at CanWell
CanWell announced today that Professor Qiang Pan-Hammarström has joined the Scientific Advisory Board (SAB) at CanWell. Professor Pan-Hammarström is a leading researcher in studying the genetic mechanisms and treatment of primary immunodeficiency diseases, including B cell development, immunoglobuli…
18
2021-05
CanWell submits to US FDA the Investigational New Drug (IND) for its TLR7 agonist CAN1012 for Cancer Treatment
CanWell Pharma announced today that its independently developed innovative drug, TLR7 agonist, was submitted to the US Food and Drug Administration (FDA) for Investigational New Drug (IND) application and was accepted for review. CAN1012 is an innovative Toll-like receptor (TLR) 7 sma…